Anastrozole Dosage and Administration for Hormone-Receptor-Positive Breast Cancer

Dosing Regimen

The optimal duration of anastrozole treatment for adjuvant treatment of early breast cancer is 5 years, as recommended by the American Society of Clinical Oncology 1

Anastrozole should not be prescribed for breast cancer risk reduction in premenopausal women, according to the National Comprehensive Cancer Network 2, 3

Prior to initiating anastrozole, clinicians should evaluate patients for baseline fracture risk and measure bone mineral density, as suggested by the American College of Clinical Oncology 3
Patients should be informed about potential side effects including joint stiffness and arthralgias, vasomotor symptoms, hypertension, dry eyes, and vaginal dryness, as reported by the Journal of Clinical Oncology 3

Anastrozole should be used with caution in postmenopausal women with moderate bone mineral density loss, and consider bone-protective agents such as bisphosphonates and RANKL inhibitors for patients at risk, as recommended by the National Osteoporosis Foundation 3
All patients receiving anastrozole should be encouraged to exercise regularly and take adequate calcium and vitamin D supplements, as suggested by the American College of Sports Medicine 3

For postmenopausal women with hormone-receptor-positive breast cancer, anastrozole 1 mg/day is one of the recommended aromatase inhibitors, along with letrozole and exemestane, as recommended by the European Society for Medical Oncology 4
The choice between these agents should consider the patient's comorbidities and potential side effect profiles, as suggested by the American Society of Clinical Oncology 5